Skip to main content

Table 3 Univariate and Multivariate analysis of prognostic factors for PHC subgroup

From: Prognosis and survival analysis of patients with pancreatic cancer: retrospective experience of a single institution

Factors n(%) Univariate analysis Multivariate analysis
mOS(95%CI) χ2 p B HR(95%CI) P
Age (years)
 ≤40 9 (2.2) 7.4 (5.0-9.8) 11.211 0.024   Reference  
 41-50 53 (12.8) 14.5 (9.3-19.6)    -0.009 0.991 (0.406-2.420) 0.984
 51-60 148 (35.8) 8.6 (7.6-9.6)    0.066 1.068 (0.456-2.501) 0.880
 61-70 142 (34.4) 11.3 (9.9-12.6)    0.148 1.159 (0.496-2.707) 0.733
 ≥71 61 (14.8) 6.7 (3.8-9.6)    0.298 1.347 (0.562-3.233) 0.504
Sex
 Male 189 (45.8) 9.0 (7.8-10.2) 1.080 0.299 - - -
 Female 224 (54.2) 11.0 (9.2-12.8)    - - -
Pain on the back and loin
 No 334 (80.9) 10.0 (8.4-11.6) 0.232 0.630 - - -
 Yes 79 (19.1) 9.3 (6.8-11.8)    - - -
Smoking history
 No 254 (61.5) 10.0 (8.6-11.4) 0.292 0.589 - - -
 Yes 159 (38.5) 9.7 (8.6-11.4)    - - -
Diabetes history
 No 180 (43.6) 9.2 (7.7-10.7) 0.054 0.817 - - -
 Yes 223 (56.4) 10.0 (8.1-11.9)    - - -
CA199(U/ml)
 <37 78 (18.9) 15.5 (9.2-21.8) 33.008 0.000   Reference  
 ≥37and<200 104 (25.2) 10.7 (8.1-13.3)    0.485 1.624 (1.122-2.351) 0.010
 ≥200and<400 65 (15.7) 10.7 (8.1-13.3)    0.549 1.732 (1.142-2.628) 0.010
 ≥400and<800 72 (17.4) 9.6 (8.0-11.2)    0.498 1.646 (1.100-2.462) 0.015
 ≥800 94 (22.8) 6.4 (5.3-7.5)    0.898 2.454 (1.626-3.702) 0.000
CEA (ng/ml)
 <5 272 (65.9) 11.1 (9.7-12.5) 8.044 0.000   Reference  
 ≥5 141 (34.1) 7.1 (5.6-8.6)    0.075 1.078 (0.834-1.393) 0.566
Albumin(g/L)
 <35 61 (14.8) 6.7 (4.1-9.3) 5.050 0.025   Reference  
 ≥35 352 (85.2) 10.3 (9.0-11.6)    -0.181 0.835 (0.597-1.166) 0.290
Total bilirubin (umol/l)
 <22 155 (37.5) 9.0 (7.2-10.8) 6.096 0.107 - - -
 ≥22and<100 53 (12.8) 8.0 (5.6-10.4)    - - -
 ≥100and<200 95 (23.0) 10.7 (8.4-13.0)    - - -
 ≥200 110 (26.6) 11.3 (8.8-13.8)    - - -
Peripancreatic invasion
 No 194 (47.0) 14.0 (11.2-16.8) 17.015 0.000   Reference  
 Yes 219 (53.0) 7.4 (6.3-8.3)    0.154 1.167 (0.912-1.493) 0.219
Degree of weight loss (kg)
 <5 234 (56.7) 11.6 (10.5-12.7) 8.223 0.000   Reference  
 ≥5 179 (43.3) 8.0 (6.8-9.2)    0.296 1.345 (1.060-1.707) 0.015
NLRa
 <2 98 (23.7) 8.1 (6.1-10.1) 3.362 0.067 - - -
 ≥2 315 (76.3) 10.7 (9.3-12.1)    - - -
NLRb
 <3 206 (49.9) 9.6 (7.9-12.3) 0.079 0.779 - - -
 ≥3 207 (50.1) 10.0 (8.3-11.7)    - - -
NLRc
 <4 248 (60.0) 10.0 (8.4-11.6) 1.433 0.231 - - -
 ≥4 165 (40.0) 9.1 (7.2-11.0)    - - -
NLRd
 <5 361 (87.4) 10.0 (8.5-11.5) 4.660 0.031   Reference  
 ≥5 52 (12.6) 8.6 (7.2-10.0)    0.206 1.229 (0.878-1.721) 0.229
Operative procedure
 Without operation 99 (24.0) 6.0 (5.1-6.9) 46.087 0.000   Reference  
 Palliative operation 70 (16.9) 6.5 (4.8-8.2)    -0.300 0.741 (0.507-1.083) 0.121
 Radical resection 244 (59.1) 14.5 (11.7-17.3)    -0.583 0.558 (0.409-0.761) 0.000
Tumor size (cm)
 d<2 32 (7.7) 15.5 (3.8-27.2) 4.244 0.120 - - -
 2≤d<4 238 (57.6) 11.0 (9.4-12.6)    - - -
 d≥4 143 (34.6) 8.4 (6.8-10.0)    - - -
Hepatic metastasis
 No 370 (89.6) 11.1 (10.0-12.2) 42.481 0.000   Reference  
 Yes 43 (10.4) 5.0 (3.6-6.4)    -0.131 0.877 (0.514-1.497) 0.631
Lymph node metastasis
 No 136 (32.9) 11.3 (10.1-12.5) 18.045 0.000   Reference  
 Yes 277 (67.1) 7.2 (5.5-8.9)    0.527 1.694 (1.328-2.161) 0.000
Number of distant organ metastasis
 0 339 (82.1) 11.6 (10.0-13.2) 74.641 0.000   Reference  
 1 60 (14.5) 6.0 (4.5-7.5)    0.707 2.028 (1.286-3.199) 0.002
 ≥2 14 (3.4) 2.9 (1.0-5.1)    0.791 2.205 (1.033-4.706) 0.041
Adjuvant chemotherapy
 No 376 (91.0) 9.0 (8.0-10.0) 10.973 0.000   Reference  
 Yes 37 (9.0) 25.4 (9.1-41.7)    -0.513 0.599 (0.384-0.933) 0.023